We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel.
- Authors
Walther, Feli M.; Fisara, Petr; Allan, Mark J.; Roepke, Rainer K. A.; Nuernberger, Martin C.
- Abstract
Background: Fluralaner (Bravecto™; Merck/MSD Animal Health) is a novel systemic ectoparasiticide for dogs providing long-acting flea and tick control after a single oral dose. Milbemycin oxime and praziquantel are routinely used to control Dirofilaria immitis and intestinal worm infections in dogs. The safety of concurrent use of fluralaner and a commercially available milbemycin oxime plus praziquantel combination tablet, in particular with regard to gastrointestinal symptoms, was investigated using oral doses at or above the maximum recommended rates. Findings: Some minor and transient clinical findings were observed during the study period; however, none of these was considered to be related to concurrent treatment with fluralaner and milbemycin oxime plus praziquantel, or to the use of either product alone. Conclusions: Concurrent treatment with fluralaner, milbemycin oxime and praziquantel is well tolerated in dogs.
- Publication
Parasites & Vectors, 2014, Vol 7, Issue 1, p1
- ISSN
1756-3305
- Publication type
Article
- DOI
10.1186/s13071-014-0481-y